

# Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline

https://marketpublishers.com/r/L8A3CE2FCC3EN.html

Date: May 2011 Pages: 2 Price: US\$ 140.00 (Single User License) ID: L8A3CE2FCC3EN

## Abstracts

Yesterday Teva announced its final USFDA approval for generic Combivir (Lamivudine + Zidovudine). With this approval, Teva has been granted and Lupin has been denied the 180-day exclusivity and as per Teva's settlement with GSK (innovator), Teva will launch its generic in Q4CY11. Lupin will be able to enter only after the 180-day exclusivity - at the earliest and will be competing with all other generics as well.

We reiterate our Underperform on Lupin with target price of Rs.360 on the back of (1) declining branded generic franchise in US (2) a thin US generic pipeline (3) Increasing expenses (R&D, SGA expenses) to put pressure on margins.



## **Contents**

#### **COMPANIES MENTIONED**

LUPIN PHARMA, LPC



#### I would like to order

Product name: Lupin Looses Combivir – A Big Blow To An Already Weak FY12 Pipeline Product link: <u>https://marketpublishers.com/r/L8A3CE2FCC3EN.html</u>

> Price: US\$ 140.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/L8A3CE2FCC3EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970